-
Effectiveness of JAK inhibitors in biologics-naïve patients with rheumatoid arthritis: a population-based study Rheumatology (IF 4.7) Pub Date : 2025-04-18 Albert Tzu Ming Chuang, Daniel Hsiang-Te Tsai, Meng-Yu Weng, Huei-Kai Huang, Edward Chia-Cheng Lai
Objective We evaluated drug retention rates to compare the effectiveness of Janus kinase (JAK) inhibitors vs. tumour necrosis factor inhibitor (TNFi) biologics and non-TNFi biologics in biologics-naïve rheumatoid arthritis (RA) patients, and assessed intra-class differences among JAK inhibitors. Methods We conducted a cohort study using Taiwan’s National Health Insurance Research Database, including
-
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-17 Charlotte Jauffret, Tristan Pascart
Calcium pyrophosphate deposition (CPPD) disease is secondary to the pathological accumulation of calcium pyrophosphate (CPP) crystals inside joints and involves acute or chronic inflammatory arthritis. Epidemiological research on CPPD has been slow despite the suspected high prevalence of this condition. Here we highlight key challenges in CPPD imaging, diagnosis and nomenclature that need to be addressed
-
Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-17 Teppei Hashimoto, Kazuyuki Tsuboi, Takeo Abe, Takahiro Yoshikawa, Kazuteru Noguchi, Tetsuya Furukawa, Koji Tateishi, Yasuhiro Terashima, Nao Sibanuma, Naoto Azuma, Takashi Yamane, Kiyoshi Matsui, Akira Hashiramoto
Inflammatory cytokine levels exhibit a circadian rhythm in sera, peaking from late night to early morning in patients with rheumatoid arthritis (RA). This cytokine kinetics is a recognized therapeutic target. This clinical study aimed to evaluate the effectiveness of night-time baricitinib administration based on cytokine secretion. In this 52-week multicenter non-randomized controlled study, 122 patients
-
Bulk RNA-seq conjoined with ScRNA-seq analysis reveals the molecular characteristics of nucleus pulposus cell ferroptosis in rat aging intervertebral discs Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-17 Shipeng Chen, Jiawei Fu, Jiang Long, Chang Liu, Xuezheng Ai, Dan Long, Xue Leng, Yang Zhang, Zhengao Liao, Changqing Li, Yue Zhou, Shiwu Dong, Bo Huang, Chencheng Feng
Recently, several studies have reported that nucleus pulposus (NP) cell ferroptosis plays a key role in IDD. However, the characteristics and molecular mechanisms of cell subsets involved remain unclear. We aimed to define the key factors driving ferroptosis, and the characteristics of ferroptotic NP cells subsets during IDD. The accumulation of iron ions in NP tissues of rats caudal intervertebral
-
T cells of patients with systemic sclerosis or Sjögren’s disease display an aberrant metabolic state and memory phenotype in blood and lungs Rheumatology (IF 4.7) Pub Date : 2025-04-17 Christine Ehlers, Hannah Biermann, Thea Thiele, Jonas C Schupp, Matteo Villa, Christine Jänke, Linus M Risser, Torsten Witte, Ulrich Kalinke, Benjamin Seeliger, Theresa Graalmann
Objectives Systemic sclerosis (SSc) and Sjögren’s disease (SjD) are characterized by systemic inflammation. Although for both entities lymphocyte involvement is reported, the contribution of T cell responses to lung manifestation of SSc and SjD remains elusive. Therefore, we aimed for systematically investigating T cell responses in blood and lungs of patients with SSc or with SjD. Methods For deep
-
Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumab Rheumatology (IF 4.7) Pub Date : 2025-04-17 Roberto Depascale, Raffaele Da Mutten, Julius Lindblom, Nursen Cetrez, Leonardo Palazzo, Luca Iaccarino, Andrea Doria, Dionysis Nikolopoulos, Mariele Gatto, Ioannis Parodis
Objective To determine systemic lupus erythematosus (SLE) endotypes according to B cell immunophenotyping and serological profile and assess endotypes’ response to belimumab. Methods We analysed data from 796 patients with SLE from the phase III trial BLISS-SC. Unsupervised machine learning employing factor analysis of mixed data (FAMD) and subsequent clustering determined endotypes based on B cell
-
Fumarate drives interferon release in systemic sclerosis monocytes Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-16 Sarah Onuora
Altered metabolism of the tricarboxylic acid cycle metabolite fumarate drives activation of interferon release in systemic sclerosis monocytes, suggesting a potential therapeutic approach.
-
Upadacitinib effective for GCA in phase III trial Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-15 Sarah Onuora
In the phase III SELECT-GCA trial, upadacitinib at a dose of 15 mg daily was superior to placebo with respect to achievement of sustained remission of giant cell arteritis at 52 weeks.
-
Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-16 Aya Shimizu, Kazuhiro Kurasawa, Tomoka Hiyama, Sara Komatsu, Azusa Kikuchi, Yuhi Yoshida, Anna Hasegawa, Tomoyuki Miyao, Ayae Tanaka, Satoko Arai, Reika Maezawa, Masafumi Arima, Kei Ikeda
To identify pathways linking cytokine abnormalities to mortality via prognostic factors in patients with anti-melanoma differentiation-associated protein 5 antibodies (anti-MDA5 Ab). This study included patients with anti-MDA5 Ab whose serum was available. Serum cytokine levels were measured using a multiplex bead assay. Prognostic factors were identified using Cox regression and log-rank test. Prognostic
-
Hydroxychloroquine dose-dependently reduces the risk of incident diabetes in primary Sjögren syndrome patients on glucocorticoids: a nationwide population-based cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-16 Wei-Sheng Chen, Hui-Ching Hsu, Tzu-Min Lin, Yu-Sheng Chang, Yi-Chun Lin, Tzu-Tung Kuo, Yu-Chuan Shen, Shu-Chuan Chen, Jin-Hua Chen, Hsiang-Yen Lee, Chi-Ching Chang
Hydroxychloroquine (HCQ) is commonly used to treat Sjögren syndrome (SS). Glucocorticoids, which are commonly applied for managing primary SS (pSS), can disrupt glucose metabolism and increase diabetes mellitus (DM) risk. HCQ reduces DM risk in systemic lupus erythematosus and rheumatoid arthritis. This study aimed to investigate the relationship between HCQ and glucocorticoids in the incidence of
-
Impact of Mediterranean diet on mortality in vertebral compression fracture patients Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-16 Longyu Zhang, Yi Zhao, Jiao Xu, Shi Yin, Qiang Wang, Zhiwei Jia, Jingpei Ren, Cong Zhao, Xiaohong Mu
Vertebral compression fractures (VCF) is a common fragility fracture with high mortality worldwide. The management and prevention of VCF start with a proper nutrition. The Mediterranean diet (MD) is rich in balanced nutrients and has been shown to be beneficial for several chronic diseases. However, the association of adherence to Mediterranean diet (aMED) and prognosis of VCF patients remains unclear
-
The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-16 Juliette Marin, Penelope Bourgoin, Noemie Saverna, Celia Cartagena, Pierre Lafforgue, Jean-Marc Busnel, Nathalie Balandraud
The spike protein-specific humoral response observed after SARS-CoV- 2 vaccination is decreased in rheumatoid arthritis (RA) patients treated with rituximab (RTX). However, when analyzed immediately after vaccination, the spike-specific T-cell immune response appears to be preserved. The possible persistence of specific T cells over the long term is underexplored and could be a useful decision-making
-
Anti-β2glycoprotein I-induced neutrophil extracellular TRAPS cause endothelial activation Rheumatology (IF 4.7) Pub Date : 2025-04-16 Silvia Mancuso, Mattia Caliste, Andrea Petretto, Elisa Corsiero, Nicole Grinovero, Antonella Capozzi, Gloria Riitano, Cristiana Barbati, Simona Truglia, Cristiano Alessandri, Maurizio Sorice, Michele Bombardieri, Fabrizio Conti
Objective NETs involvement in antiphospholipid syndrome (APS) pathogenesis is known, but the role of anti-β2glycoprotein I antibodies (aβ2GPI)-induced NETs in triggering a procoagulant and proinflammatory phenotype in endothelial cells (EC) remains to be evaluated. This study investigated whether NET-aβ2GPI can activate ECs and whether NET-aβ2GPI and NET-PMA have different proteomic profiles. Methods
-
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease‐modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK‐pot" study) Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-15 Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Tore K Kvien, Burkhard F Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A Provan, Anja Strangfeld, Trokovic Nina, Jakub
ObjectiveTo assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.MethodsRA patients from 15 registries in the JAK‐pot collaboration were included. MACE incidence was analysed using two approaches: a
-
Multi‐parametric profiling of circulating immune cells identifies an expansion of CD25hi switched memory B cells in Osteoarthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-15 Neety Sahu, Yudhisthar Singh Bedi, Fiorella Grandi, William J. Maloney, Constance R. Chu, Nidhi Bhutani
-
Enhancing Predictive Biomarkers in Limited Cutaneous Systemic Sclerosis: The Role of Type I Interferon Score and Gender Considerations Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-15 Sheng Li
Click on the article title to read more.
-
Time‐dependent effect of prophylactic trimethoprim‐sulfamethoxazole on the incidence of serious infections in ANCA‐associated vasculitis: A target trial emulation study Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-15 Yun Kyu Kim, Jeffrey R Curtis, Se Rim Choi, Jina Yeo, Min Jung Kim, Yun Jong Lee, Eun Bong Lee, Jun Won Park
ObjectivesTo investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis (AAV).MethodsThis multicenter cohort study designed to emulate a target trial studied 296 patients with AAV treated with rituximab or cyclophosphamide as induction therapy. Patients were grouped
-
Effective treatment of Jak1/3 inhibitor in Blau syndrome from a multi-center retrospective study in central China. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Yangyang Hu,Pengcheng Li,Jinhua Liu,Zhipeng Zeng,Xiong Zhang,Wen Yin,Hai Xu,Jing Cai,Yikai Yu
OBJECTIVE To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort. METHODS A five-year, multi-center, retrospective, observational study was conducted across seven centers, focusing on genetic profiles and the clinical manifestations of cohort
-
Increased school absence among children with juvenile idiopathic arthritis - a national matched comparison study. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Malthe Jessen Pedersen,Christian Høst,Stefan Nygaard Hansen,Jens Klotsche,Kirsten Minden,Bent Deleuran,Bodil Hammer Bech
OBJECTIVE This study compares rates of school absence (SA) of all children with juvenile idiopathic arthritis (JIA) attending public Danish schools to peers both before and after JIA diagnosis. Further, we aimed to investigate the role of socioeconomic status (SES) on the possible association. METHODS We performed a register-based matched cohort study. We included all children attending public Danish
-
Patients' perspectives and experiences with medication for gout: A thematic synthesis of qualitative studies. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Olav Tvedten,Sacha Bossina,Muguet Koobasi,Allison Jaure,Brian Liang,Clarice Tang,Kathleen Tymms,Gabor Major,Ayano Kelly
OBJECTIVE To describe patients' perspectives and experiences of medications for gout to inform patient-centred practice. METHODS Systematic review (MEDLINE, Embase, PsychInfo, CINAHL) and thematic analysis of studies using qualitative methodology to May 2023. RESULTS Five dominant themes were identified in 45 studies involving 1203 patients:- denying illness, negotiating uncertainty, juggling competing
-
Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Amir A Razmjou,Angela Pham,Elizabeth R Volkmann,Veena K Ranganath
-
Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Racheal Githumbi,Claire E H Barber,Susan J Bartlett,Karine Toupin-April,Marinka Twilt,Diane Lacaille,Cheryl Barnabe,Kiran Dhiman,Alison M Hoens,Adrian Grebowicz,Tara McMillan,Jessica Widdifield
OBJECTIVE To review methods for developing and endorsing Quality Measures (QMs) to inform a national quality measurement framework for rheumatology care in Canada. METHODS We conducted a rapid environmental scan of measure development organizations from Canada, the United Kingdom, the United States and Australia. Major phases in the development of QMs were abstracted. The results were reviewed and
-
Update to a Systematic Review on Quality Measures for Rheumatoid Arthritis. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Racheal Githumbi,Steven J Katz,Jessica Widdifield,Claire E H Barber
OBJECTIVE This work aims to provide an update on a previously published systematic review on quality measures (QMs) in rheumatoid arthritis (RA) to inform future measure development and endorsement efforts. METHODS We searched published and grey literature sources from January 2018-July 2023. Included sources were limited to those that targeted RA patients, either exclusively or alongside other rheumatic
-
Arthritis Mutilans in Psoriatic Arthritis: The Consequences of Delayed Treatment. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Deepti Agarwal,Kavita Krishna
-
Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? New Iatrogenic Disease Case Series From CanRIO. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Yuliya Lytvyn,Megan E Himmel,Carrie Ye,Shahin Jamal,Alexandra P Saltman,
-
How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Gabriele De Marco,Helena Marzo-Ortega,Philip S Helliwell
-
Frailty and Associated Outcomes in Patients with Vasculitis. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Sebastian E Sattui,John Stadler,Renee L Borchin,Cristina Burroughs,Laura Gandolfo,David Cuthbertson,Christine Yeung,Kalen Larson,Peter A Merkel,Robert Spiera,
OBJECTIVE To describe the frequency and outcomes associated with self-reported frailty in patients with vasculitis. METHODS VascStrong is a longitudinal study utilizing the Vasculitis Patient-Powered Research Network, an internet-based cohort of patients with vasculitis. Data collected included patient global assessment (PGA) and several domains of the Patient-Reported Outcomes Measurement Information
-
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Elizabeth R Volkmann,Shervin Assassi,Christopher P Denton,Rozeta Simonovska,Steven Sambevski,Margarida Alves,Elana J Bernstein
OBJECTIVE Compare the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) based on serological status. METHODS In a post-hoc analysis of the SENSCIS trial (nintedanib vs placebo in SSc-ILD; NCT02597933), we analyzed the rate of decline in forced vital capacity (FVC) over 52 weeks in 3 subsets: positive for anti-centromere antibody (ACA), positive for anti-RNA polymerase
-
Revisiting Magnetic Resonance Imaging Structural Lesions in the Sacroiliac Joints. J. Rheumatol. (IF 3.6) Pub Date : 2025-04-15 Denis Poddubnyy
-
Efficacy and Safety of Zimlovisertib, Ritlecitinib and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-14 Spencer I. Danto, Mikhail Salganik, Anindita Banerjee, Pawel Hrycaj, Irina Jashi, Negin Shojaee, Ravi Shankar P. Singh, Steven A. Gilbert, Karen Page, Elena Peeva, Michael S. Vincent, Jean S. Beebe
ObjectiveTo evaluate the efficacy and safety of zimlovisertib (interleukin‐1 receptor‐associated kinase 4 inhibitor) in combination with ritlecitinib (a Janus kinase [JAK] 3 and tyrosine kinase expressed in hepatocellular carcinoma [TEC] kinase family inhibitors) or tofacitinib (a JAK inhibitor) vs tofacitinib alone.MethodsThis phase 2 study randomized patients with moderate to severe active RA to
-
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): insights from an international survey of patients with psoriatic arthritis Rheumatology (IF 4.7) Pub Date : 2025-04-13 Andre L Ribeiro, Shikha Singla, M Cameron Hay, Nicholas Chronis, Wilson Liao, Christine Lindsay, Enrique R Soriano, Vinod Chandran, Jean-Guillaume Letarouilly, Philip J Mease, Fabian Proft
Objectives Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease in which a significant proportion of patients remain refractory to existing therapies. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiated a project aimed at unraveling the reasons for treatment failures in PsA, culminating in the establishment of definitions for Difficult-to-Treat
-
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study Rheumatology (IF 4.7) Pub Date : 2025-04-13 Luca Moroni, Batani Veronica, Gabriele D Gallina, Giovanni Benanti, Maria Cilona, Adriana Cariddi, Marco Lanzillotta, Giulia Danè, Umberto Tanzini, Marco Matucci-Cerinic, Lorenzo Dagna
Objectives To evaluate the efficacy and safety of a step-down treatment approach using mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA) in a real-life single-centre cohort. The study aimed to assess outcomes following a transition from high-dose (300 mg/4 weeks) to low-dose (100 mg/4 weeks) mepolizumab after achieving remission. Methods This retrospective study included EGPA patients
-
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics. Rheumatology (IF 4.7) Pub Date : 2025-04-12 Jasvinder A Singh,Larry R Hearld,Seth Eisen,W Winn Chatham,Sonali Narain,Narender Annapureddy,Diane L Kamen,Kimberly Trotter,Vikas Majithia,Cathy Lee Ching,Zineb Aouhab,Swamy Venuturupalli,Daniel J Wallace,Rosalind Ramsey-Goldman,Alfred Kim,Maureen McMahon,S Sam Lim,Kalpana Bhairavarasu,Alexa Meara,Kenneth Kalunian,Mark Beasley,
OBJECTIVE To examine the clinic outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. METHODS We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019-2024 (including the COVID-pandemic). We collected Organizational Readiness to Implement Change (ORIC), and Team Learning and Psychological Safety Survey (TLPSS) at baseline
-
Comment on: In clinical hand osteoarthritis research, self-reported pain questionnaires do not reflect the patient experience: Reply. Rheumatology (IF 4.7) Pub Date : 2025-04-12 Coen van der Meulen,Margreet Kloppenburg
-
New X for VEXAS: haploidentical allogeneic hematopoietic cell transplantation in VEXAS syndrome. Rheumatology (IF 4.7) Pub Date : 2025-04-12 Stefan Hug,Andreas Riedel,Christoph Faul,Wolfgang Bethge,Benedikt Obermaier,Sebastian Saur,Claudia Lengerke,Jörg Henes
-
Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis Rheumatology (IF 4.7) Pub Date : 2025-04-12 Ali Y Ayla, Naveen R Kalavar, Mark Pimentel, Walter Morales, Laura K Hummers, Ami A Shah, Michael Hughes, Zsuzsanna H McMahan
Objectives Functional antibodies play a role in SSc gastrointestinal (GI) disease, but their clinical relevance is unclear. We examined GI and extraintestinal features associated with anti-M3R antibodies in SSc patients. Methods In a cohort enriched for GI symptoms, SSc patients were tested for anti-M3R antibodies using an enzyme-linked immunosorbent assay. High-titers were defined a priori based on
-
Lipid nanoparticles with PDL1-encoding mRNA spread tolerance Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-11 Maria Papatriantafyllou
Lipid nanoparticle carriers of immunosuppressive mRNA shape tolerogenic antigen-presenting cells that inhibit arthritis progression in mice.
-
Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-11 Ilayda Gunes, Elana J. Bernstein, Shawn E. Cowper, Gauri Panse, Niki Pradhan, Lucy Duran Camacho, Nicolas Page, Elizabeth Bundschuh, Alyssa Williams, Mary Carns, Kathleen Aren, Sarah Fantus, Elizabeth R. Volkmann, Heather Bukiri, Chase Correia, Vijaya B. Kolachalama, F. Perry Wilson, Seamus Mawe, J. Matthew Mahoney, Monique Hinchcliff
The modified Rodnan skin score (mRSS), a measure of systemic sclerosis (SSc) skin thickness, is agnostic to inflammation and vasculopathy. Previously, we demonstrated the potential of neural network-based digital pathology applied to SSc skin biopsies as a quantitative outcome. Here, we leverage deep learning and histologic analyses of clinical trial biopsies to decipher SSc skin features ‘seen’ by
-
Expert perspective: How, When, and Why to Potentially Stop Anti‐resorptive Drugs in Osteoporosis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-11 Giovanni Adami, Kenneth G Saag
-
Neutrophil extracellular traps associated RNA impedes CD4+ Treg differentiation by TLR7‐IRF7 axis in ankylosing spondylitis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-11 Zhikun Li, Jiajie Lin, Zepeng Su, Yipeng Zeng, Yi Zhou, Jinteng Li, Wenhui Yu, Guiwen Ye, Guan Zheng, Zipeng Xiao, Yanfeng Wu, Huiyong Shen, Zhongyu Xie
-
Reply to: Enhancing Predictive Biomarkers in Limited Cutaneous Systemic Sclerosis: The Role of Type I Interferon Score and Gender Considerations Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-11 Stefano Di Donato, Christopher P. Denton, Francesco Del Galdo
Click on the article title to read more.
-
Decoding the adaptive immune repertoire for disease prediction Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-10 Laura F. Su
-
Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-10 Andrew Östör, Eugen Feist, Prodromos Sidiropoulos, Jérôme Avouac, Martin Rebella, Rajaie Namas, Erin McDearmon-Blondell, Tianming Gao, Ivan Lagunes-Galindo, Sander Strengholt, Devy Zisman, Suzan Attar
Upadacitinib (UPA), an oral Janus kinase inhibitor, has shown efficacy with an acceptable safety profile in rheumatoid arthritis (RA) clinical trials. To assess the real-world effectiveness and safety of UPA in adults with moderate-to-severe RA in the UPHOLD observational study. Co-primary endpoints were: (i) proportion of patients achieving disease activity score in 28 joints using C-reactive protein
-
CCL23 is a potential biomarker for antineutrophil cytoplasmic antibody–associated vasculitis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-10 Weiwei Hao, Qianqian Liu, Xiaoping Li, Yiran Xu, Wenjuan Guan, Lei Zhang, Fang Dong, Wenjun Cao, Shengyun Liu, Wei Li
The present cohort study aimed to evaluate the value of CCL23 in diagnosis, disease activity, and prognosis in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). CCL23 levels in serum samples from 317 patients with AAV and 83 healthy controls (HCs) were measured using a customized immune response kit. Patients with AAV had significantly elevated CL23 levels compared with
-
Acute vison loss due to granulomatosis with polyangiitis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-10 Hirotaka Yamamoto, Yoshinori Taniguchi
Click on the article title to read more.
-
Histologic predictors of kidney outcomes in lupus nephritis: reevaluating the role of segmental glomerulosclerosis in the chronicity index Rheumatology (IF 4.7) Pub Date : 2025-04-10 Denisse N Tinajero-Sánchez, Erick Y Zúñiga-González, María F Zavala-Miranda, Adriana Hernández-Andrade, Valeria Navarro-Sánchez, Alberto Nordmann-Gomes, Emiliano Rivero-Otamendi, Norma O Uribe-Uribe, Juan M Mejia-Vilet
Objectives There is a call to improve the histological classification of lupus nephritis (LN). We assessed the association between histological lesions and kidney outcomes. Methods We assessed 430 participants with biopsy-proven LN diagnosed between 2008 and 2020. All participants had follow-up for ≥3 years. The activity and chronicity lesions comprised in the National Institutes of Health activity
-
Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden Rheumatology (IF 4.7) Pub Date : 2025-04-10 Annica Dominicus, Arthur Mageau, Ngoc V Nguyen, Karin Blomkvist Sporre, Elisabet Svenungsson, Elizabeth V Arkema
Objectives It is unknown to what extent updated treatment recommendations regarding glucocorticoids (GC) and hydroxychloroquine (HCQ) for patients with systemic lupus erythematosus (SLE) have been incorporated into clinical practice. Based on filled dispensations we examined treatment patterns the first 5 years after SLE diagnosis in Sweden, trends over time and relationship to patient characteristics
-
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs. Rheumatology (IF 4.7) Pub Date : 2025-04-09 Sizheng Steven Zhao,Stephanie R Harrison,Ben Thompson,Max Yates,Joe Eddison,Antoni Chan,Nick Clarke,Nadia Corp,Charlotte Davis,Lambert Felix,Kalveer Flora,William J Gregory,Gareth T Jones,Christopher A Lamb,Helena Marzo-Ortega,Daniel J Murphy,Harry Petrushkin,Virinderjit Sandhu,Raj Sengupta,Stefan Siebert,Danielle A Van Der Windt,Dale Webb,Zenas Z N Yiu,Karl Gaffney
-
Right atrial reservoir strain as an early predictor of pulmonary hypertension development in systemic sclerosis: a single-centre pilot study Rheumatology (IF 4.7) Pub Date : 2025-04-09 Veronica Codullo, Mauro Acquaro, Alessandra Greco, Micaela Lia, Bianca Lucia Palermo, Laura Scelsi, Sandra Schirinzi, Annalisa Turco, Giovanni Zanframundo, Carlomaurizio Montecucco, Adele Valentini, Lorenzo Cavagna, Stefano Ghio
Introduction Regular screening for pulmonary hypertension (PH) is recommended in patients with SSc for the early detection and treatment of pulmonary arterial hypertension. Whether Doppler echocardiography may predict subsequent development of PH is still unknown. In this context, there is growing awareness of the potential importance of right atrial function in reflecting an initial overload of the
-
Risk factors for non-response to initial IVIG plus methylprednisolone therapy in children with Kawasaki disease Rheumatology (IF 4.7) Pub Date : 2025-04-09 Minna Yang, Mingming Zhang, Hongmao Wang, Xiaohui Li
Objectives Intravenous immunoglobulin (IVIG) plus corticosteroids is recommended as the initial intensified therapy for high-risk IVIG-resistant Kawasaki disease (kDa) patients. However, some patients still require additional rescue therapy despite this treatment. This study aimed to identify risk factors associated with non-response to initial IVIG plus methylprednisolone (mPSL) therapy in high-risk
-
Vascular liver disorders in patients with antiphospholipid syndrome: a national retrospective multicentre study Rheumatology (IF 4.7) Pub Date : 2025-04-09 Mathilde Katims, Marc Pineton de Chambrun, Cecile Yelnik, Ada Clarke, Matthias Papo, Zahir Amoura, Marc Lambert, Pascale Roland-Nicaise, Aurélie Plessier, Laure Delaval, Thomas Papo, Pierre-Emmanuel Rautou, Nathalie Costedoat Chalumeau, Karim Sacre
Objective Antiphospholipid syndrome (APS) is an acquired autoimmune prothrombotic condition. Vascular liver disorders (VLD), such as portal vein thrombosis (PVT), Budd-Chiari syndrome (BCS) and porto-sinusoidal vascular disorder (PSVD), are rare and related to an underlying hypercoagulable state in most cases. We aimed to describe the clinical and immunological features of APS patients with VLD. Methods
-
Letter to the Editor: Methodological Considerations for "Pro‐inflammatory Dietary Pattern and the Risk of Female Gout" Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-08 Fusen Chen, Jiatao Li, Tiejuan Shao
Click on the article title to read more.
-
Responsive and monophasic lupus nephritis: prevalence, associations, and outcomes Rheumatology (IF 4.7) Pub Date : 2025-04-08 Fadi Kharouf, Pankti Mehta, Virginia Carrizo-Abarza, Qixuan Li, Laura P Whittall Garcia, Dafna D Gladman, Zahi Touma
Objectives Lupus nephritis (LN) is associated with significant renal morbidity, although some patients may experience a responsive and monophasic course. We aimed to assess the proportion of LN patients with such a course and identify its associated baseline characteristics. Methods This retrospective study included SLE patients from an observational cohort who developed LN at or after clinic entry
-
Exploring Future Studies and Treatment Implications in Non-Articular Pain in Early RA Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-06 Charis F. Meng, Yvonne C. Lee, Susan J Bartlett, Vivian P Bykerk
Click on the article title to read more.
-
Sex- and gender-based personalized medicine in rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-07 Elizabeth R. Volkmann, Carol Feghali-Bostwick
Although autoimmune rheumatic diseases are more prevalent in women than men, few clinical trials report findings on the basis of sex and gender. Future clinical trials should report sex and gender differences in treatment and safety outcomes in a standardized manner to improve outcomes for all patients.
-
IgG4-related disease and other fibro-inflammatory conditions Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-07 Francesco Peyronel, Emanuel Della-Torre, Federica Maritati, Maria L. Urban, Ingeborg Bajema, Nicolas Schleinitz, Augusto Vaglio
-
Serum proteomic signatures prior to the diagnosis of rheumatoid arthritis demonstrate evolving biological pathways and identify specific periods of disease development Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-07 Samir Rachid Zaim, Adam K. Savage, Mark A. Gillespie, Jazmine Castillo, Christy Bennett, Troy R Torgerson, Lynne A. Becker, Michael Mahler, LauraKay Moss, Marie L. Feser, Jess D. Edison, Ted R. Mikuls, V. Michael Holers, Xiao‐jun Li, Kevin D. Deane
ObjectiveThis longitudinal case‐control study evaluated serum proteomics prior to a clinical diagnosis of rheumatoid arthritis (i.e. pre‐RA) to evaluate biologic pathways of disease development and inform prediction of timing of onset of future disease.MethodsPatients (cases, n=213) meeting the 1987 American College of Rheumatology (ACR) classification criteria for RA, and matched controls without
-
GPA presenting as Strawberry Gingivitis – Methodological aspects Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-07 Diane van der Woude, Ingeborg M. Bajema, Ulrich Specks
Click on the article title to read more.
-
Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: results from a randomised, controlled trial Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-05 Shuji Asai, Toshihisa Kojima, Hajime Ishikawa, Nobumasa Miyake, Masanari Kodera, Hisanori Hasegawa, Yasumori Sobue, Yasuhide Kanayama, Hiromi Shimada, Yuji Hirano, Toshihiko Hidaka, Takayoshi Fujibayashi, Takuya Matsumoto, Tomonori Kobayakawa, Hidekata Yasuoka, Takefumi Kato, Masahiro Hanabayashi, Yuko Kaneko, Masahiro Tada, Koichi Murata, Kenta Misaki, Masahiko Ando, Yachiyo Kuwatsuka, Mochihito Suzuki
The present non-inferiority study was designed to compare the effect of discontinuing versus continuing methotrexate (MTX) alongside certolizumab pegol (CZP) on maintaining low disease activity (LDA) in rheumatoid arthritis (RA) patients already stable on combination therapy. This multicentre, open-label, randomised, controlled trial included RA patients with sustained LDA (Clinical Disease Activity
-
Infrapatellar fat pad as a source of biomarkers and therapeutic target for knee osteoarthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2025-04-05 Betzabeth Pereira Herrera, Kaj Emanuel, Pieter J. Emans, Martijn van Griensven, Berta Cillero-Pastor
Osteoarthritis (OA) is a multifactorial and highly prevalent disease in elderly adults; however, its pathogenesis, diagnosis, and treatment are unmet needs nowadays. Research efforts have focused on elucidating the molecular mechanisms involved in the pathogenesis, onset, and progression of OA to facilitate early detection and effective therapeutic approaches. Infrapatellar fat pad (IPFP) represents